Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals gets orphan drug designation for setmelanotide in Japan
Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment
Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $66.00 at Needham & Company LLC
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...
Charles Schwab Investment Management Inc. Acquires 6,384 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...
TipRanks on MSN19d
Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization
Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...
Nasdaq2d
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients
Rhythm Pharmaceuticals, Inc. has announced a collaboration with the Raymond A. Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma ...
Yahoo Finance2d
Rhythm Pharmaceuticals, Inc. (RYTM)
Over the last 7 days, the United States market has dropped 3.1%, yet it remains up by 13% over the past year with earnings anticipated to grow by 14% per annum in the coming years. In this dynamic ...
Seeking Alpha22d
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...
Morningstar2d
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...
Yahoo Finance21d
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth
Given this risk, we thought we'd take a look at whether Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...